Market News / Story
AB Science SA (AB) H1 Loss Widens; Trials Pushed Back
·
AB Science SA reported a H1 2026 operating loss of €10.4M vs €2.7M a year ago and net loss of €9.0M vs €5.2M. Following a GCP inspection, it targets resuming its AML Phase 1 in Q1 2027 and ALS Phase 3 in Q4 2027, and secured a firm offer for €25–€39M trial insurance. Material Details #DetailAI Analyst View1H1 op. loss €10.4M vs €2.7MWider loss signals higher cash burn and potential financing needs.2H1 net loss €9.0M vs €5.2MBottom-line deterioration pressures runway and…